Haemophilia

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Haemophilia
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Prolonged bleeding, easy bruising, joint pain
Complications	Hemarthrosis, intracranial hemorrhage, anemia
Onset	Childhood
Duration	Lifelong
Types	Haemophilia A, Haemophilia B
Causes	Genetic mutation in F8 or F9 gene
Risks	Family history
Diagnosis	Coagulation test, genetic testing
Differential diagnosis	von Willebrand disease, platelet disorders
Prevention	Genetic counseling
Treatment	Factor replacement therapy, desmopressin
Medication	Factor VIII, Factor IX
Prognosis	N/A
Frequency	1 in 5,000 males (Haemophilia A), 1 in 30,000 males (Haemophilia B)
Deaths	Rare with treatment

Hemophilia is a group of rare inherited bleeding disorders that affect the blood's ability to clot. These conditions are caused by mutations in the genes encoding for clotting factors, proteins that play a crucial role in blood coagulation. Hemophilia is typically classified into two main types, hemophilia A and hemophilia B, depending on the specific clotting factor deficiency. Hemophilia A is caused by a deficiency in clotting factor VIII (FVIII), while hemophilia B is due to a deficiency in clotting factor IX (FIX).

A woman suffering from Hemophilia

Signs and Symptoms

Individuals with hemophilia may experience prolonged and spontaneous bleeding episodes, often after minor injuries or without any apparent cause. The severity of bleeding depends on the degree of clotting factor deficiency. Common symptoms include:

• Bleeding into joints, causing pain, swelling, and stiffness
• Muscle hemorrhages
• Easy bruising and prolonged bleeding after injuries or surgery
• Blood in urine or stool
• Nosebleeds
• Bleeding gums
• Severe cases of hemophilia can lead to life-threatening complications, such as intracranial hemorrhages or damage to vital organs.

Genetics

Haemophilia family tree

Hemophilia is primarily inherited in an X-linked recessive pattern, meaning the disease predominantly affects males. Females who carry one copy of the mutated gene may have mild symptoms or be asymptomatic carriers. Hemophilia A is caused by mutations in the F8 gene, while hemophilia B results from mutations in the F9 gene.

Diagnosis

Hemophilia is typically diagnosed based on clinical symptoms, family history, and laboratory tests that measure the levels and activity of clotting factors. Genetic testing may be used to confirm the diagnosis and identify the specific gene mutation responsible.

Treatment

There is currently no cure for hemophilia, but the condition can be managed through the replacement of missing clotting factors. This is achieved through the intravenous administration of concentrated clotting factors derived from donated human blood or produced through recombinant DNA technology. Other treatments may include:

• Antifibrinolytic agents to prevent blood clots from breaking down
• Pain relievers and anti-inflammatory medications to manage joint pain and swelling
• Physical therapy to improve joint mobility and muscle strength
• Vaccinations to prevent infections, such as hepatitis A and B

In some cases, patients may undergo gene therapy to introduce a functional copy of the affected gene, offering the potential for long-term improvement in clotting factor levels.

Epidemiology

Hemophilia is a rare condition, affecting approximately 1 in 5,000 male births for hemophilia A and 1 in 30,000 male births for hemophilia B. The disease occurs in all ethnic groups and geographical regions.

History

Hemophilia has been recognized as a hereditary bleeding disorder since ancient times, but the term "hemophilia" was first introduced by Friedrich Hopff in 1828. In the early 20th century, hemophilia became widely known as the "royal disease" due to its presence in the descendants of Queen Victoria of England.

Research Directions

Current research in hemophilia focuses on improving treatment options, understanding the underlying genetic and molecular mechanisms, and developing novel therapies to provide a potential cure. Areas of ongoing research include:

• Gene therapy: Gene therapy aims to deliver a functional copy of the affected gene to the patient's cells, potentially offering long-term improvement in clotting factor levels. Several clinical trials are underway to evaluate the safety and efficacy of gene therapy in treating hemophilia A and B.
• Novel clotting factors: Researchers are working on the development of new clotting factor concentrates with improved properties, such as longer half-lives or higher activity levels. These novel factors could potentially lead to less frequent infusions, improved clotting control, and a reduced risk of inhibitor development.
• Inhibitor management: Inhibitors are antibodies that some patients with hemophilia develop in response to clotting factor replacement therapy, rendering the treatment ineffective. Current research seeks to better understand the factors that contribute to inhibitor development and explore strategies to prevent or eradicate inhibitors in affected patients.
• Alternative coagulation therapies: Scientists are exploring alternative therapies that target other components of the coagulation cascade, bypassing the need for specific clotting factor replacement. Such therapies may benefit patients with inhibitors or those who cannot receive factor replacement for other reasons.
• Biomarkers and personalized medicine: The identification of biomarkers that predict treatment response, bleeding risk, and inhibitor development could help tailor treatment strategies to individual patients, improving outcomes and reducing complications.
• Quality of life and psychosocial research: Living with hemophilia can have a significant impact on a patient's quality of life, affecting physical, emotional, and social well-being. Researchers are working to better understand these challenges and develop interventions to support patients and their families.

See Also

• Von Willebrand disease
• Blood clotting
• Coagulation factors
• Gene therapy
• Inherited bleeding disorders

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
• Lillicrap D. The molecular and cellular biology of coagulation factor VIII. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. 2nd ed. Wiley-Blackwell; 2010:3-11.
• White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J; Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.
• Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187-197.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia